Australia has approved psilocybin as a treatment for severe depression, but the rollout faces major practical challenges. Only a handful of psychiatrists are authorized to prescribe it, treatment costs over $20,000 per person, and there are no standardized training programs for therapists. The therapy can profoundly alter patients’ beliefs and worldviews, raising ethical concerns about proper support during and after treatment. The article proposes solutions including national training standards, better funding access, and stronger safeguards for vulnerable patients.